JP2017522312A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522312A5 JP2017522312A5 JP2017502194A JP2017502194A JP2017522312A5 JP 2017522312 A5 JP2017522312 A5 JP 2017522312A5 JP 2017502194 A JP2017502194 A JP 2017502194A JP 2017502194 A JP2017502194 A JP 2017502194A JP 2017522312 A5 JP2017522312 A5 JP 2017522312A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic composition
- doses
- antigen
- combination
- combination according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002163 immunogen Effects 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 35
- 239000000427 antigen Substances 0.000 claims description 23
- 102000036639 antigens Human genes 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 238000002347 injection Methods 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 16
- 230000028993 immune response Effects 0.000 claims description 11
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- -1 MAGE-A1 Proteins 0.000 claims description 6
- 150000001413 amino acids Chemical group 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 5
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
- 108090000288 Glycoproteins Proteins 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 4
- 241000701806 Human papillomavirus Species 0.000 claims description 4
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 4
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 4
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- 230000010354 integration Effects 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims description 2
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 108700012439 CA9 Proteins 0.000 claims description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 2
- 101710132601 Capsid protein Proteins 0.000 claims description 2
- 108010033547 Carbonic Anhydrase I Proteins 0.000 claims description 2
- 102100025518 Carbonic anhydrase 1 Human genes 0.000 claims description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 2
- 101710094648 Coat protein Proteins 0.000 claims description 2
- 101710201734 E3 protein Proteins 0.000 claims description 2
- 101150029707 ERBB2 gene Proteins 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims description 2
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 claims description 2
- 102100028092 Homeobox protein Nkx-3.1 Human genes 0.000 claims description 2
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 2
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 claims description 2
- 101000578249 Homo sapiens Homeobox protein Nkx-3.1 Proteins 0.000 claims description 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 2
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims description 2
- 108010061833 Integrases Proteins 0.000 claims description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 2
- 108010010995 MART-1 Antigen Proteins 0.000 claims description 2
- 101710125418 Major capsid protein Proteins 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 108090000015 Mesothelin Proteins 0.000 claims description 2
- 102000003735 Mesothelin Human genes 0.000 claims description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 2
- 101710141454 Nucleoprotein Proteins 0.000 claims description 2
- XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 2
- 101710083689 Probable capsid protein Proteins 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 101710132594 Protein E6 Proteins 0.000 claims description 2
- 101710132595 Protein E7 Proteins 0.000 claims description 2
- 241000710960 Sindbis virus Species 0.000 claims description 2
- 101500008206 Sindbis virus Spike glycoprotein E2 Proteins 0.000 claims description 2
- 108010002687 Survivin Proteins 0.000 claims description 2
- 108010017842 Telomerase Proteins 0.000 claims description 2
- 108090000333 Transgelin Proteins 0.000 claims description 2
- 102000003932 Transgelin Human genes 0.000 claims description 2
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims description 2
- 102000003425 Tyrosinase Human genes 0.000 claims description 2
- 108060008724 Tyrosinase Proteins 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229910052804 chromium Inorganic materials 0.000 claims description 2
- 239000011651 chromium Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 210000000852 deltoid muscle Anatomy 0.000 claims description 2
- 108010051081 dopachrome isomerase Proteins 0.000 claims description 2
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 claims description 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 108700004026 gag Genes Proteins 0.000 claims description 2
- 101150098622 gag gene Proteins 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 102000003898 interleukin-24 Human genes 0.000 claims description 2
- 108090000237 interleukin-24 Proteins 0.000 claims description 2
- 239000002603 mannosidase inhibitor Substances 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000000716 merkel cell Anatomy 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 2
- 201000008026 nephroblastoma Diseases 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000007764 o/w emulsion Substances 0.000 claims description 2
- 108091008819 oncoproteins Proteins 0.000 claims description 2
- 102000027450 oncoproteins Human genes 0.000 claims description 2
- 108700004029 pol Genes Proteins 0.000 claims description 2
- 101150088264 pol gene Proteins 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 102000016914 ras Proteins Human genes 0.000 claims description 2
- 230000008707 rearrangement Effects 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 102220036548 rs140382474 Human genes 0.000 claims description 2
- FLNVBBPBGKOJHN-KKAOYSRWSA-N sivmac Chemical compound O=C([C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O FLNVBBPBGKOJHN-KKAOYSRWSA-N 0.000 claims description 2
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 102100034349 Integrase Human genes 0.000 claims 3
- 101710121417 Envelope glycoprotein Proteins 0.000 claims 2
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 25
- 102100034343 Integrase Human genes 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462024797P | 2014-07-15 | 2014-07-15 | |
| US201462024792P | 2014-07-15 | 2014-07-15 | |
| US62/024,792 | 2014-07-15 | ||
| US62/024,797 | 2014-07-15 | ||
| PCT/US2015/040453 WO2016011083A1 (en) | 2014-07-15 | 2015-07-14 | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017522312A JP2017522312A (ja) | 2017-08-10 |
| JP2017522312A5 true JP2017522312A5 (enExample) | 2018-08-23 |
Family
ID=53776968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502194A Pending JP2017522312A (ja) | 2014-07-15 | 2015-07-14 | Ｔｌｒ４アゴニストアジュバント及びレンチウイルスベクターを用いたプライム・ブーストレジメン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20170196954A1 (enExample) |
| EP (1) | EP3169352A1 (enExample) |
| JP (1) | JP2017522312A (enExample) |
| KR (1) | KR20170032373A (enExample) |
| AU (1) | AU2015289773A1 (enExample) |
| CA (1) | CA2955015A1 (enExample) |
| MX (1) | MX2017000630A (enExample) |
| WO (1) | WO2016011083A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250095754A (ko) | 2016-04-15 | 2025-06-26 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
| EP3443000B1 (en) | 2016-04-15 | 2025-11-12 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| WO2018022946A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| WO2018148180A2 (en) * | 2017-02-07 | 2018-08-16 | Immune Design Corp. | Materials and methods for identifying and treating cancer patients |
| AU2018235835A1 (en) | 2017-03-16 | 2019-09-05 | Alpine Immune Sciences, Inc. | PD-L2 variant immunomodulatory proteins and uses thereof |
| AU2018236224B2 (en) | 2017-03-16 | 2024-01-04 | Alpine Immune Sciences, Inc. | PD-L1 variant immunomodulatory proteins and uses thereof |
| JP7386083B2 (ja) | 2017-03-16 | 2023-11-24 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｄ８０バリアント免疫調節タンパク質及びその使用 |
| KR102758545B1 (ko) | 2017-10-10 | 2025-01-23 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| TW202500579A (zh) | 2017-10-18 | 2025-01-01 | 美商艾爾潘免疫科學有限公司 | 變異型icos 配位體免疫調節蛋白及相關組合物及方法 |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| EP3743084A4 (en) * | 2018-01-24 | 2021-12-08 | Virogin Biotech Canada Ltd | RECOMBINANT VIRAL VACCINES |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| AU2019339332A1 (en) * | 2018-09-10 | 2021-04-08 | Torque Therapeutics, Inc. | Antigen-specific T lymphocytes and methods of making and using the same |
| CN113544144A (zh) | 2018-09-19 | 2021-10-22 | 高山免疫科学股份有限公司 | 变体cd80融合蛋白和相关构建体的方法和用途 |
| EP3628735A1 (en) | 2018-09-25 | 2020-04-01 | Centre National De La Recherche Scientifique | Antisense rna targeting pmp22 for the treatment of charcot-marie-tooth 1a disease |
| JP7713886B2 (ja) | 2018-11-30 | 2025-07-28 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｄ８６バリアント免疫調節タンパク質およびその使用 |
| WO2020131656A1 (en) * | 2018-12-17 | 2020-06-25 | Immune Design Corp. | Pathogen-associated molecular pattern molecules and rna immunogenic compositions and methods of using the compositions for treating cancer |
| MX2021012607A (es) | 2019-04-17 | 2022-03-11 | Alpine Immune Sciences Inc | Metodos y usos de proteinas de fusion de ligando icos (icosl) variante. |
| CA3178882A1 (en) | 2020-05-08 | 2021-11-11 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins and methods of use thereof |
| EP4333869A1 (en) | 2021-05-07 | 2024-03-13 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
| WO2023172883A1 (en) | 2022-03-07 | 2023-09-14 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses |
| AU2023356958A1 (en) | 2022-10-04 | 2025-04-03 | Alpine Immune Sciences, Inc. | Mutated taci-fc fusion proteins for use in the treatment of autoantibody-mediated diseases |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
| US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| US4569794A (en) | 1984-12-05 | 1986-02-11 | Eli Lilly And Company | Process for purifying proteins and compounds useful in such process |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5352449A (en) | 1986-05-30 | 1994-10-04 | Cambridge Biotech Corporation | Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant |
| US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5443964A (en) | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
| US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
| EP0342926B1 (en) | 1988-05-17 | 1994-09-28 | Mycogen Plant Science, Inc. | Plant ubiquitin promoter system |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5256643A (en) | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| EP0584266B1 (en) | 1991-05-06 | 2003-09-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Recombinant virus expressing carcinoembryonic antigen and methods of use thereof |
| US5273965A (en) | 1992-07-02 | 1993-12-28 | Cambridge Biotech Corporation | Methods for enhancing drug delivery with modified saponins |
| EP0651656A1 (en) | 1992-07-08 | 1995-05-10 | Schering Corporation | Use of gm-csf as a vaccine adjuvant |
| US5786148A (en) | 1996-11-05 | 1998-07-28 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a novel prostate-specific kallikrein |
| CA2140343A1 (en) | 1992-07-17 | 1994-02-03 | Sean M. Sullivan | Method and reagent for treatment of animal diseases |
| DE9319879U1 (de) | 1993-12-23 | 1994-03-17 | Ems-Inventa AG, Zürich | Sequentiell Coextrudierte Kühlflüssigkeitsleitung |
| US5688506A (en) | 1994-01-27 | 1997-11-18 | Aphton Corp. | Immunogens against gonadotropin releasing hormone |
| US6447796B1 (en) | 1994-05-16 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| EP1167378B1 (en) | 1994-07-15 | 2011-05-11 | University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| DE69534702T2 (de) | 1994-09-23 | 2006-08-24 | The University Of British Columbia, Vancouver | Verfahren zur erhöhung der expression von endogenen peptiden tragenden mhc klasse i molekulen |
| DK0784483T3 (da) | 1994-10-03 | 2001-03-26 | Us Gov Health & Human Serv | Præparat indeholdende et rekombinant virus, der udtrykker et antigen, og et rekombinant virus, der udtrykker et immunstimul |
| US5981215A (en) | 1995-06-06 | 1999-11-09 | Human Genome Sciences, Inc. | Human criptin growth factor |
| US5955306A (en) | 1996-09-17 | 1999-09-21 | Millenium Pharmaceuticals, Inc. | Genes encoding proteins that interact with the tub protein |
| EP0961830A1 (en) | 1997-01-29 | 1999-12-08 | Neurosearch A/S | EXPRESSION VECTORS AND METHODS FOR $i(IN VIVO) EXPRESSION OF THERAPEUTIC POLYPEPTIDES |
| US5840871A (en) | 1997-01-29 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Prostate-associated kallikrein |
| EP1630235A3 (en) | 1997-02-25 | 2009-05-27 | Corixa Corporation | Compounds for immunodiagnosis of prostate cancer and method for their use |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| CA2317549C (en) | 1998-01-05 | 2006-04-11 | University Of Washington | Composition for enhancing transport through lipid-containing membranes, and uses thereof |
| CZ298347B6 (cs) | 1998-02-05 | 2007-09-05 | Glaxosmithkline Biologicals S.A. | Fúzní protein z rodiny MAGE, kódová sekvence nukleové kyseliny, vektor, hostitelská bunka, vakcina a použití fúzního proteinu pro výrobu vakciny |
| EP1073734B1 (en) | 1998-04-15 | 2009-09-23 | Ludwig Institute for Cancer Research Ltd. | Tumor associated nucleic acids and uses therefor |
| GB2337755B (en) | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
| CN100419079C (zh) | 1998-07-14 | 2008-09-17 | 科里克萨有限公司 | 用于治疗和诊断前列腺癌的组合物和方法 |
| BR9912671A (pt) | 1998-08-07 | 2001-05-02 | Univ Washington | Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização |
| DE60040274D1 (de) | 1999-03-10 | 2008-10-30 | Phogen Ltd | Verabreichung von nukleinsäuren und proteinen an zellen |
| CA2370697C (en) | 1999-04-19 | 2012-03-06 | Smithkline Beecham Biologicals S.A. | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| ES2308989T3 (es) | 1999-08-09 | 2008-12-16 | Targeted Genetics Corporation | Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios. |
| US20020130430A1 (en) | 2000-12-29 | 2002-09-19 | Castor Trevor Percival | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
| US20030077829A1 (en) | 2001-04-30 | 2003-04-24 | Protiva Biotherapeutics Inc.. | Lipid-based formulations |
| US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| ES2337454T3 (es) | 2001-11-30 | 2010-04-26 | The Government Of The Usa, As Represented By The Secretary Department Of Health And Human Services | Peptidos agonistas de antigenos especificos de la protasa, y usos de los mismos. |
| US7141540B2 (en) | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
| US7550296B2 (en) | 2004-12-01 | 2009-06-23 | Bayer Schering Pharma Ag | Generation of replication competent viruses for therapeutic use |
| AU2007354917B2 (en) | 2006-09-26 | 2013-06-06 | Access To Advanced Health Institute | Vaccine composition containing synthetic adjuvant |
| US8563523B2 (en) | 2007-09-07 | 2013-10-22 | University Of Georgia Research Foundation, Inc. | Synthetic lipid A derivative |
| HRP20180184T1 (hr) | 2007-12-11 | 2018-04-06 | The University Of North Carolina At Chapel Hill | Retrovirusni vektori s modificiranim polipurinskim nizom |
| JP5830015B2 (ja) | 2009-06-05 | 2015-12-09 | インフェクシャス ディズィーズ リサーチ インスティチュート | 合成グルコピラノシル脂質アジュバント |
| PT2456786E (pt) | 2009-07-24 | 2014-03-25 | Immune Design Corp | Vetores lentivirais pseudotipados com uma glicoproteína do envelope do vírus sindbis |
| AU2012243039B2 (en) * | 2011-04-08 | 2017-07-13 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| EP2831095B1 (en) * | 2012-03-30 | 2018-11-28 | Immune Design Corp. | Lentiviral vector particles having improved transduction efficiency for cells expressing dc-sign |
| US8323662B1 (en) | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
-
2015
- 2015-07-14 MX MX2017000630A patent/MX2017000630A/es unknown
- 2015-07-14 CA CA2955015A patent/CA2955015A1/en not_active Abandoned
- 2015-07-14 AU AU2015289773A patent/AU2015289773A1/en not_active Abandoned
- 2015-07-14 EP EP15745647.6A patent/EP3169352A1/en not_active Withdrawn
- 2015-07-14 US US15/326,052 patent/US20170196954A1/en not_active Abandoned
- 2015-07-14 KR KR1020177003844A patent/KR20170032373A/ko not_active Withdrawn
- 2015-07-14 WO PCT/US2015/040453 patent/WO2016011083A1/en not_active Ceased
- 2015-07-14 JP JP2017502194A patent/JP2017522312A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017522312A5 (enExample) | ||
| US20190032064A1 (en) | Personalized Delivery Vector-Based Immunotherapy and Uses Thereof | |
| JP6921750B2 (ja) | ペプチドミニ遺伝子発現系を含むリステリアベースの組成物およびその使用方法 | |
| CA3212964A1 (en) | Tumor neoantigenic peptides | |
| TW201639594A (zh) | 利用重組李斯特菌菌株之組合療法 | |
| Xiao et al. | Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice | |
| JP2018515588A (ja) | 個別化送達ベクターに基づく免疫療法とその使用 | |
| Dai et al. | PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines | |
| Jemon et al. | An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy | |
| JP7384896B2 (ja) | 主要組織適合遺伝子複合（ｍｈｃ）クラスｉｉ－発現癌細胞ワクチン、及び統合免疫応答を生じさせるための使用方法 | |
| US20230293650A1 (en) | Individualized therapeutic anticancer vaccine | |
| Neukirch et al. | Adenovirus based virus-like-vaccines targeting endogenous retroviruses can eliminate growing colorectal cancers in mice | |
| Wang et al. | The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC‐205/CD205 receptor on dendritic cells | |
| JP2022071130A (ja) | ワクチンとして使用するためのエキソソームアンカータンパク質を発現するヌクレオチド配列 | |
| Lescaille et al. | Efficacy of DNA vaccines forming e7 recombinant retroviral virus-like particles for the treatment of human papillomavirus-induced cancers | |
| Li et al. | Antigen-clustered nanovaccine achieves long-term tumor remission by promoting B/CD 4 T cell crosstalk | |
| Chen et al. | Induction of HCA587-specific antitumor immunity with HCA587 protein formulated with CpG and ISCOM in mice | |
| JP2017516462A5 (enExample) | ||
| Hart et al. | Stable expression of lentiviral antigens by quality-controlled recombinant Mycobacterium bovis BCG vectors | |
| Lowe et al. | Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase | |
| US20180036400A1 (en) | Double engineered hiv-1 envelopes | |
| Luo et al. | Emerging strategies for advancing peptide vaccines | |
| AU2015236147A1 (en) | Mosaic HIV-1 sequences and uses thereof | |
| CN108025044A (zh) | 免疫原性降钙素原前体肽 | |
| WO2007059030A2 (en) | Llo-encoding dna/nucleic acid vaccines and methods comprising same |